Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Apixaban Versus Antiplatelet Drugs or no Antithrombotic Drugs After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation: A Randomised Phase II Clinical Trial
Brief Summary: There is a marked lack of evidence on the optimal prevention of ischaemic stroke in patients with atrial fibrillation and a recent intracerebral haemorrhage (ICH) during treatment with oral anticoagulation. These patients are currently treated with vitamin K antagonists, DOACs, antiplatelet drugs, or no antithrombotic treatment, depending on personal and institutional preferences. Treatment with a direct oral anticoagulant like apixaban might be an attractive alternative in terms of a low risk of recurrent ICH, while at the same time being effective for the prevention of ischaemic stroke. This study aims to obtain reliable estimates of the rates of vascular death or non-fatal stroke in patients with atrial fibrillation and a recent anticoagulation-associated intracerebral haemorrhage who are treated with apixaban versus those who are treated with antiplatelet drugs or no antithrombotic drug at all.

This study has a multi-centre, phase II, randomised, open-label clinical trial with blinded outcome assessment design.


Options:
A: Arm Label: Antithrombotic treatment; Type: EXPERIMENTAL; Interventions: Drug: Antithrombotic Agent | Arm Label: No antithrombotic treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Antithrombotic Agent; Assigned to Arm(s): Antithrombotic treatment
B: Arm Label: Start oral anticoagulant (OAC); Type: EXPERIMENTAL; Interventions: Drug: Apixaban, Drug: Rivaroxaban, Drug: Edoxaban, Drug: Dabigatran, Drug: Acenocoumarol, Drug: Phenindione, Drug: Warfarin | Arm Label: Do not start oral anticoagulant (OAC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Start oral anticoagulant (OAC) | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Start oral anticoagulant (OAC) | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Start oral anticoagulant (OAC) | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Start oral anticoagulant (OAC) | Intervention Type: DRUG; Name: Acenocoumarol; Assigned to Arm(s): Start oral anticoagulant (OAC) | Intervention Type: DRUG; Name: Phenindione; Assigned to Arm(s): Start oral anticoagulant (OAC) | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Start oral anticoagulant (OAC)
C: Arm Label: Telemetric Bluetooth-enabled home BP monitors; Type: EXPERIMENTAL; Interventions: Device: A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci | Arm Label: Standard clinical care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci; Assigned to Arm(s): Telemetric Bluetooth-enabled home BP monitors
D: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Avoiding oral anticoagulants; Type: OTHER; Interventions: Drug: Aspirin, Drug: Carbasalate calcium, Drug: Clopidogrel, Drug: Dipyridamole, Other: No antithrombotic treatment | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Avoiding oral anticoagulants | Intervention Type: DRUG; Name: Carbasalate calcium; Assigned to Arm(s): Avoiding oral anticoagulants | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Avoiding oral anticoagulants | Intervention Type: DRUG; Name: Dipyridamole; Assigned to Arm(s): Avoiding oral anticoagulants | Intervention Type: OTHER; Name: No antithrombotic treatment; Assigned to Arm(s): Avoiding oral anticoagulants

Answer: D